Skip to content

News Releases


All Releases
View Summary Vical Announces News Release and Conference Call Schedule for 2009 Financial Results
Feb 4, 2010
PDF 9.3 KB
View Summary Vical Completes Enrollment in Allovectin-7(r) Phase 3 Trial for Metastatic Melanoma
Jan 28, 2010
PDF 13.6 KB
View Summary Vical Updates Vaccine Development Programs for CMV and Pandemic Influenza
Jan 26, 2010
PDF 8.0 KB
View Summary Vical Names Richard T. Kenney, M.D., Vice President of Clinical Development
Jan 14, 2010
PDF 8.7 KB
View Summary Vical Licensee AnGes MG Reaches Agreement With FDA For Phase 3 Trial of Collategene(TM) Angiogenesis Product
Jan 12, 2010
PDF 9.7 KB
View Summary Vical Announces Licensee's Approval of ONCEPT(TM) Therapeutic Melanoma Vaccine for Dogs
Jan 11, 2010
PDF 10.5 KB
View Summary Vical Secures $25 Million Issuer Managed Equity Facility With Azimuth Opportunity, Ltd.
Jan 8, 2010
PDF 7.9 KB
View Summary Mechanism of Action for Vical's Vaxfectin(R) Adjuvant Expands Potential Applications
Jan 7, 2010
PDF 9.7 KB
View Summary Vical Confirms Advantages of DNA Technology Platform With Vaccine for H1N1 Influenza
Dec 29, 2009
PDF 10.8 KB
View Summary Vical's Allovectin-7(R) Phase 3 Trial Receives Positive Review From Safety Monitoring Board
Dec 28, 2009
PDF 11.1 KB
View Summary Vical and the University of Washington Receive U.S. Patent for Herpes Simplex DNA Vaccine
Dec 22, 2009
PDF 10.8 KB
View Summary Vical Advocates DNA Vaccine Approach With Pandemic Influenza Experts
Dec 9, 2009
PDF 9.5 KB
View Summary Vical Completes Final Patient Follow-Up in TransVax(TM) CMV Vaccine Phase 2 Trial
Nov 23, 2009
PDF 8.8 KB
View Summary Vical Added to NASDAQ Biotechnology Index
Nov 16, 2009
PDF 9.9 KB
View Summary Vical's DNA Vaccine Technology Addresses Challenges of Emerging Diseases
Nov 10, 2009
PDF 7.9 KB
View Summary Vical Reports Third Quarter 2009 Financial Results and Progress in Key Development Programs
Nov 4, 2009
PDF 16.4 KB
View Summary Vical Announces News Release and Conference Call Schedule for Third Quarter 2009 Financial Results
Oct 28, 2009
PDF 7.6 KB
View Summary Vical to Present at BIOCOM Investor Conference
Oct 27, 2009
PDF 6.7 KB
View Summary Vical's Vaxfectin® Adjuvant Drives 200-Fold Increase in Antibody Responses With Sanofi-Pasteur Fluzone® Seasonal Influenza Vaccine
Oct 26, 2009
PDF 9.6 KB
View Summary Vical's TransVax(TM) CMV Vaccine Elicits Long-Term Immune Responses in Phase 2 Trial
Oct 7, 2009
PDF 8.0 KB
View Summary U.S. Navy to Fund Vical's H1N1 Pandemic Influenza (Swine Flu) Vaccine
Oct 1, 2009
PDF 7.9 KB
View Summary Vical Licensee Sanofi-aventis Completes Enrollment in Phase 3 Angiogenesis Trial
Sep 28, 2009
PDF 8.7 KB
View Summary Vical Presents Positive Preclinical Results with Vaxfectin(R)-Formulated, Peptide-based Cancer Vaccine
Sep 24, 2009
PDF 9.3 KB
View Summary Detailed Data From Vical's TransVax(TM) CMV Vaccine Phase 2 Trial Presented in Late-Breaker Session at ICAAC
Sep 14, 2009
PDF 9.9 KB
View Summary Vical Pandemic Influenza Vaccine Demonstrates Cross-reactivity Against California, Texas and Mexico H1N1 Strains
Sep 10, 2009
PDF 9.3 KB
View Summary Vical Receives $2.5 Million Payment for Funding of Allovectin-7(r) Phase 3 Trial
Sep 8, 2009
PDF 8.3 KB
View Summary Vical Receives Broad U.S. Patent for Vaxfectin(R)-Formulated DNA Vaccines for Influenza; Coverage Includes All Seasonal and Pandemic Strains
Sep 3, 2009
PDF 8.9 KB
View Summary Vical to Present At Upcoming Investor Conferences
Sep 2, 2009
PDF 7.2 KB
View Summary Vical Reports Second Quarter 2009 Financial Results and Updates Progress in Key Programs
Aug 6, 2009
PDF 15.5 KB
View Summary Vical and Teva Establish Sales and Marketing Agreement for Allovectin-7(r) in Israel
Aug 3, 2009
PDF 10.4 KB
View Summary Vical Announces News Release and Conference Call Schedule For Second Quarter 2009 Financial Results
Jul 30, 2009
PDF 7.6 KB
View Summary Federated Kaufmann Funds to Invest $10 Million in Vical
Jul 28, 2009
PDF 7.3 KB
View Summary Vical TransVax(tm) CMV Vaccine Achieves Promising Interim Clinical Results in Phase 2 Trial
Jul 8, 2009
PDF 11.7 KB
View Summary Vical Announces News Release and Conference Call/Webcast Schedule to Present TransVax(tm) CMV Vaccine Phase 2 Interim Efficacy Results
Jul 7, 2009
PDF 7.7 KB
View Summary Vical H1 Influenza Vaccine Delivers Robust Preclinical Results With 100% Response
Jun 30, 2009
PDF 8.9 KB
View Summary Vical Receives Milestone Payment From Merck & Co., Inc.
Jun 22, 2009
PDF 7.1 KB
View Summary Vical Advances RapidResponse(tm) DNA Vaccine Platform Under $6 Million Grant From NIH
Jun 18, 2009
PDF 10.1 KB
View Summary Vical Announces Issuance of U.S. Patent for Universal Influenza Vaccine Approach
Jun 3, 2009
PDF 8.5 KB
View Summary Vical to Present At Upcoming Investor Conferences
Jun 1, 2009
PDF 7.0 KB
View Summary Vical to Present Update On Pandemic Influenza Vaccine Program and Overview of Pivotal Phase 3 Melanoma Trial At ASGT Conference
May 27, 2009
PDF 7.0 KB
View Summary Vical Receives Additional Commitment in Registered Direct Offering
May 26, 2009
PDF 7.7 KB
View Summary Vical to Raise $15.4 Million in Registered Direct Offering
May 22, 2009
PDF 7.7 KB
View Summary Vical Advances H1N1 Pandemic Influenza (Swine Flu) Vaccine
May 21, 2009
PDF 8.6 KB
View Summary Vical to Open NASDAQ Stock Market
May 20, 2009
PDF 7.4 KB
View Summary Vical Receives $2.5 Million Payment for Continued Funding of Allovectin-7(r) Phase 3 Trial
May 18, 2009
PDF 8.9 KB
View Summary Vical Grants Johns Hopkins Bloomberg School of Public Health Academic License for Core Technology
May 14, 2009
PDF 7.6 KB
View Summary Vical Reports First Quarter 2009 Financial Results and Progress in Key Programs
May 7, 2009
PDF 14.5 KB
View Summary Vical and U.S. Navy to Expedite Development of H1N1 Pandemic Influenza (Swine Flu) Vaccine
May 6, 2009
PDF 8.5 KB
View Summary Vical Announces News Release and Conference Call Schedule for First Quarter 2009 Financial Results
Apr 30, 2009
PDF 7.6 KB
View Summary Vical Updates Lead Vaccine Programs At NFID Vaccine Research Conference and Addresses Potential Response to H1N1 Swine Influenza Outbreak
Apr 28, 2009
PDF 12.1 KB
View Summary Vical Reports Publication of Key Research Findings for Immunotherapeutic Herpes Vaccine
Apr 23, 2009
PDF 10.1 KB
View Summary Vical's Vaxfectin(r) Adjuvant Named One of 100 Great Investigational Drugs in Eighth Annual Ranking by Editors of R&D Directions
Apr 9, 2009
PDF 9.5 KB
View Summary Vical's Allovectin-7(r) Phase 3 Trial Receives Positive Review From Safety Monitoring Board
Mar 24, 2009
PDF 10.4 KB
View Summary Vical to Present At Upcoming Investor Conferences
Mar 5, 2009
PDF 6.9 KB
View Summary Vical Reports 2008 Financial Results and Progress in Product Development Programs
Feb 17, 2009
PDF 14.9 KB
View Summary Vical Presents Pandemic Influenza Vaccine Results and Outlook At WHO Meeting
Feb 13, 2009
PDF 9.4 KB
View Summary Vical Receives $2.3 Million Payment for Continued Funding of Allovectin-7(r) Phase 3 Trial
Feb 11, 2009
PDF 9.0 KB
View Summary Vical Announces News Release and Conference Call Schedule for 2008 Financial Results
Feb 10, 2009
PDF 7.6 KB
View Summary Vical Announces Issuance of U.S. Patent No. 7,470,675 for Composition, Delivery and Use of Gene-Based Interferon-Omega
Jan 14, 2009
PDF 8.3 KB
View Summary Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
Dec 11, 2008
PDF 11.6 KB
View Summary SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
Dec 9, 2008
PDF 10.7 KB
View Summary Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey
Dec 3, 2008
PDF 12.5 KB
View Summary Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
Dec 1, 2008
PDF 7.7 KB
View Summary Vical Announces Strategic Restructuring and Staff Reduction
Nov 21, 2008
PDF 8.0 KB
View Summary Vical Executive Alain Rolland Named AAPS Fellow
Nov 17, 2008
PDF 9.4 KB
View Summary Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
Nov 12, 2008
PDF 10.2 KB
View Summary U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin(R) Adjuvant
Nov 6, 2008
PDF 11.5 KB
View Summary Vical Reports Third Quarter 2008 Financial Results and Continued Progress in Product Development Program
Nov 5, 2008
PDF 13.3 KB
View Summary Vical to Present at Upcoming Investor Conferences
Nov 4, 2008
PDF 6.6 KB
View Summary Vical Announces News Release and Conference Call Schedule For Third Quarter 2008 Financial Results
Oct 29, 2008
PDF 7.9 KB
View Summary Vical to Present at Upcoming Investor Conferences
Oct 23, 2008
PDF 6.4 KB
View Summary Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
Oct 8, 2008
PDF 10.9 KB
View Summary Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
Oct 7, 2008
PDF 7.1 KB
View Summary Vical to Present at UBS Global Life Sciences Conference
Sep 15, 2008
PDF 6.5 KB
View Summary Vaxfectin(R)-formulated Measles DNA Vaccine Could Address Unmet Need for Infants
Aug 21, 2008
PDF 11.1 KB
View Summary Karolinska Institutet to Test Vical’s Vaxfectin® Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
Aug 19, 2008
PDF 10.9 KB
View Summary Vical Reports Second Quarter and First Six Months 2008 Financial Results and Highlights in Product Development Programs
Aug 5, 2008
PDF 13.5 KB
View Summary Vical Announces News Release and Conference Call Schedule for Second Quarter 2008 Financial Results
Jul 29, 2008
PDF 8.4 KB
View Summary Vical Receives $1 Million Milestone Payment From AnGes MG for Angiogenesis Program
Jul 22, 2008
PDF 7.9 KB
View Summary Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
Jul 17, 2008
PDF 12.5 KB
View Summary Vical to Present Phase 1 Data for Vaxfectin(R)-Formulated Pandemic Influenza DNA Vaccines
Jul 14, 2008
PDF 8.9 KB
View Summary Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
Jun 25, 2008
PDF 10.4 KB
View Summary Vical Pandemic Influenza Vaccines Provide Complete Protection in Animal Studies; The Journal of Infectious Diseases Publishes H5N1 Challenge Data
Jun 16, 2008
PDF 9.3 KB
View Summary Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
Jun 12, 2008
PDF 10.5 KB
View Summary Promise of Vical's CMV Vaccine Noted by Independent Experts
Jun 5, 2008
PDF 10.0 KB
View Summary Vical to Present at Needham & Company Biotechnology and Medical Technology Conference
Jun 4, 2008
PDF 6.5 KB
View Summary Vical to Present at Upcoming Investor Conferences
May 12, 2008
PDF 6.8 KB
View Summary Vical Reports First Quarter 2008 Financial Results and Updates Key Development Programs
May 8, 2008
PDF 12.8 KB
View Summary Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results
May 1, 2008
PDF 7.4 KB
View Summary Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report
Apr 23, 2008
PDF 11.4 KB
View Summary Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
Apr 3, 2008
PDF 9.8 KB
View Summary Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product
Mar 28, 2008
PDF 9.9 KB
View Summary Vical to Present at Cowen and Company Health Care Conference
Mar 12, 2008
PDF 6.5 KB
View Summary Vical to Present at BIO and BVGH Global Health Partnering Event
Mar 4, 2008
PDF 7.3 KB
View Summary Vical Reports 2007 Financial Results and Progress in Product Development Programs
Feb 21, 2008
PDF 12.4 KB
View Summary Vical Announces News Release and Conference Call Schedule for 2007 Financial Results
Feb 14, 2008
PDF 7.3 KB
View Summary Vical to Present at BIO CEO and Investor Conference
Feb 5, 2008
PDF 6.6 KB
View Summary Vical Expands Portfolio of CMV Vaccine Technologies Through License Agreement With The Wistar Institute
Jan 22, 2008
PDF 10.7 KB
View Summary Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
Jan 17, 2008
PDF 7.8 KB
View Summary Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
Jan 7, 2008
PDF 7.5 KB
View Summary Vical Expands Clinical Testing of DNA Vaccine Against H5N1 Pandemic Influenza
Dec 6, 2007
PDF 10.0 KB
View Summary Vical Launches Redesigned Website
Dec 4, 2007
PDF 6.5 KB
View Summary Vical Presentation at Military Pandemic Influenza Workshop
Nov 30, 2007
PDF 6.9 KB
View Summary Vical Reports Third Quarter 2007 Financial Results and Progress in Product Development Programs
Oct 31, 2007
PDF 12.3 KB
View Summary Vical to Present at Investor Conferences
Oct 30, 2007
PDF 7.0 KB
View Summary Vical Announces News Release and Conference Call Schedule for Third Quarter 2007 Financial Results
Oct 25, 2007
PDF 7.8 KB
View Summary Interim Safety Data Favorable for Vical's Phase 2 Trial of DNA Vaccine Against CMV
Oct 17, 2007
PDF 9.2 KB
View Summary Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
Oct 9, 2007
PDF 10.7 KB
View Summary Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
Sep 20, 2007
PDF 9.1 KB
View Summary Vical to Present at Upcoming Investor Conferences
Sep 5, 2007
PDF 7.2 KB
View Summary Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
Aug 28, 2007
PDF 10.0 KB
View Summary Multiple NIH Phase 2 HIV Vaccine Trials Using Vical's Technology Produce Encouraging Results
Aug 22, 2007
PDF 9.7 KB
View Summary Vical Names Andrew de Guttadauro Vice President, Corporate Development
Aug 20, 2007
PDF 7.9 KB
View Summary Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Aug 7, 2007
PDF 13.2 KB
View Summary Vical Announces News Release and Conference Call Schedule for Second Quarter 2007 Financial Results
Jul 31, 2007
PDF 7.8 KB
View Summary Vical Reaches Initial Enrollment Milestone in Phase 2 Trial of DNA Vaccine Against CMV
Jul 11, 2007
PDF 9.6 KB
View Summary Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
Jun 18, 2007
PDF 10.3 KB
View Summary Vical Receives $6 Million Grant From NIH to Advance RapidResponse(TM) DNA Vaccine Platform
Jun 12, 2007
PDF 10.9 KB
View Summary Vical Demonstrates Safety and Tolerability of IL-2 DNA Delivery with Electroporation
Jun 3, 2007
PDF 10.9 KB
View Summary Vical Introduces RapidResponse(TM) DNA Vaccine Cell-Free Platform Designed to Accelerate Vaccine Production During Infectious Disease Outbreaks
Jun 2, 2007
PDF 10.9 KB
View Summary Vaxfectin(TM)-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
May 31, 2007
PDF 10.4 KB
View Summary Vical to Present at American Society of Gene Therapy Annual Meeting
May 30, 2007
PDF 7.4 KB
View Summary Vical to Present at Scientific and Investor Conferences
May 29, 2007
PDF 8.5 KB
View Summary Vical Announces Webcast of CEO Presentation at Bank of America Health Care Conference
May 23, 2007
PDF 7.1 KB
View Summary Vical's Vaxfectin(TM) Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
May 23, 2007
PDF 9.6 KB
View Summary Vical DNA Vaccine Elicits Lasting Memory T-cell Immune Responses in Humans
May 14, 2007
PDF 8.2 KB
View Summary Vical Reports First Quarter 2007 Financial Results; Highlights Progress in Key Development Programs
May 3, 2007
PDF 13.2 KB
View Summary Vical Wins Final Decision Upholding Key Japanese Patent
May 1, 2007
PDF 7.5 KB
View Summary Vical Announces News Release and Conference Call Schedule for First Quarter 2007 Financial Results
Apr 26, 2007
PDF 7.7 KB
View Summary Vical Expands Testing of Vaxfectin(TM) Adjuvant to U.S. Navy Malaria Vaccine Program
Apr 19, 2007
PDF 10.4 KB
View Summary Vical's Vaxfectin(TM) Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
Apr 11, 2007
PDF 11.0 KB
View Summary Vical Announces Licensee's Conditional Approval of Therapeutic Cancer Vaccine for Dogs
Mar 26, 2007
PDF 8.9 KB
View Summary Vical Reports 2006 Financial Results
Feb 20, 2007
PDF 13.3 KB
View Summary Vical Announces News Release and Conference Call Schedule for 2006 Financial Results
Feb 13, 2007
PDF 7.7 KB
View Summary Vical Announces Participation on Pandemic Vaccine Panel at BIO CEO and Investor Conference
Feb 8, 2007
PDF 7.1 KB
View Summary Vical Highlights Transition to Phase 3 Trial With Allovectin-7(R) for Metastatic Melanoma
Jan 24, 2007
PDF 9.3 KB
View Summary Vical Initiates Pivotal Phase 3 Trial of Allovectin-7(R) as First-line Therapy for Metastatic Melanoma
Jan 4, 2007
PDF 11.0 KB
View Summary Vical Announces Webcast of CEO Presentation at Lazard Capital Markets Third Annual Life Sciences Conference
Nov 21, 2006
PDF 7.0 KB
View Summary Vical Announces Webcast of CFO Presentation at BioCom San Diego Investor Conference
Nov 8, 2006
PDF 6.9 KB
View Summary Vical Reports Third Quarter 2006 Financial Results
Nov 2, 2006
PDF 14.3 KB
View Summary Vical Acquires Angiogenesis and Poloxamer Patents from Valentis
Oct 31, 2006
PDF 7.4 KB
View Summary Vical Announces Webcast of CEO Presentation at Rodman & Renshaw Healthcare Conference
Oct 30, 2006
PDF 7.0 KB
View Summary Vical Successfully Opposes PowderMed's European Patent No. 0431135
Oct 26, 2006
PDF 7.2 KB
View Summary Vical Announces News Release and Conference Call Schedule for Third Quarter 2006 Financial Results
Oct 21, 2006
PDF 8.3 KB
View Summary Single Injection of Vical's Avian Flu DNA Vaccine Provides 100% Protection in Ferrets
Oct 20, 2006
PDF 9.2 KB
View Summary Temasek Holdings to Invest $25 Million in Vical
Oct 19, 2006
PDF 9.2 KB
View Summary Vical to Raise $12.5 Million in Registered Direct Offering
Oct 16, 2006
PDF 7.4 KB
View Summary Vical's Vaxfectin(TM) Adjuvant Boosts Immune Response to Seasonal Influenza Vaccine; Suggests Potential Dose-Sparing Application for Pandemic Flu
Oct 14, 2006
PDF 9.1 KB
View Summary Vical Demonstrates Novel Method of Predicting DNA Vaccine Effectiveness
Oct 14, 2006
PDF 8.5 KB
View Summary Vical Grants Additional Academic Licenses for Core Technology
Sep 19, 2006
PDF 8.5 KB
View Summary Vical Announces Webcast of CEO Presentation at UBS Global Life Sciences Conference
Sep 18, 2006
PDF 6.7 KB
View Summary Vical Extends Patent Coverage for Vaxfectin(TM) Adjuvant to Conventional Vaccines
Sep 13, 2006
PDF 8.7 KB
View Summary Broad T-Cell Immunity Against HIV Generated in Prime-Boost Vaccine Phase 1 Trial
Aug 31, 2006
PDF 9.0 KB
View Summary Vical DNA Delivery Technology Enters Clinical Trial for Therapeutic HIV Vaccine
Aug 22, 2006
PDF 9.2 KB
View Summary Vical Completes $9.8 Million Registered Direct Offering
Aug 10, 2006
PDF 7.0 KB
View Summary Vical Reports Second Quarter 2006 Financial Results
Aug 1, 2006
PDF 14.1 KB
View Summary Vical Announces Management Changes
Jul 21, 2006
PDF 8.4 KB
View Summary Vical Avian Flu Vaccine Data Meets NIH Grant Funding Requirement
Jun 7, 2006
PDF 9.3 KB
View Summary Vical Announces Webcast of CEO Presentation at Needham Biotechnology and Medical Technology Conference
Jun 6, 2006
PDF 6.9 KB
View Summary Vical Names Ronald B. Moss, M.D., Vice President, Clinical Development
Jun 5, 2006
PDF 8.0 KB
View Summary Vical Highlights DNA Vaccine Technology Advances at ASGT Annual Meeting
Jun 5, 2006
PDF 9.9 KB
View Summary West Nile Virus DNA Vaccine Produces Neutralizing Antibodies in All Fully Vaccinated Volunteers in Phase 1 Trial
Jun 1, 2006
PDF 10.1 KB
View Summary Vical and AnGes MG to Collaborate on Allovectin-7(R) and Begin Phase 3 Pivotal Trial
May 30, 2006
PDF 12.7 KB
View Summary Vical Announces News Release and Conference Call Schedule to Discuss Collaborative Agreement With AnGes MG for Allovectin-7(R)
May 29, 2006
PDF 7.5 KB
View Summary Vical Announces Webcast of CEO Presentation at Rodman & Renshaw 3rd Annual Global Healthcare Conference
May 9, 2006
PDF 7.1 KB
View Summary Vical's DNA Vaccine Provides Complete Protection Against Avian Influenza and Demonstrates Cross-protection Against Multiple Human Flu Strains in Animal Studies
May 2, 2006
PDF 10.9 KB
View Summary Vical Reports First Quarter 2006 Financial Results
May 2, 2006
PDF 13.8 KB
View Summary Vical's DNA Vaccine With Vaxfectin(TM) Adjuvant Advances in Pandemic Influenza Program
Mar 31, 2006
PDF 8.5 KB
View Summary Vical Announces Webcast of Presentations at Analyst and Investor Day Focused on Avian Influenza and Cytomegalovirus Vaccine Programs
Mar 30, 2006
PDF 7.5 KB
View Summary Vical Licensee Sanofi-Aventis Releases Phase 2b Angiogenesis Data and Plans for Phase 3
Mar 13, 2006
PDF 9.3 KB
View Summary Vical Announces Webcast of CEO Presentation at Cowen & Co. Health Care Conference
Feb 28, 2006
PDF 7.0 KB
View Summary Ebola DNA Vaccine Produces Immune Responses in All Fully Vaccinated Volunteers in Phase 1 Trial
Feb 21, 2006
PDF 11.0 KB
View Summary Vical Reports 2005 Financial Results
Feb 14, 2006
PDF 12.6 KB
View Summary Vical Opens Phase 2 Trial of DNA Vaccine Against CMV
Feb 1, 2006
PDF 9.2 KB
View Summary Vical Files $70 Million Shelf Registration
Jan 27, 2006
PDF 7.2 KB
View Summary Vical Licenses Core Technology to Stanford, Harvard and Yale
Jan 24, 2006
PDF 8.7 KB
Showing 1-176 of 176 Page: 1